Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations

Askanase, A. D., Furie, R. A., Dall’Era, M., Bomback, A. S., Schwarting, A., Zhao, M.-H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R. A., van Vollenhoven, R., & Urowitz, M. B. (2024). Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations. Lupus Science & Medicine, 11(1), e001124. https://doi.org/10.1136/lupus-2023-001124
Authors:
Anca Askanase
Richard Furie
Maria Dall’Era
Andrew S. Bomback
Andreas Schwarting
Ming‐Hui Zhao
Ian N Bruce
Munther A. Khamashta
Bernie Rubin
Angela Carroll
Mark Daniels
Roger A. Levy
Ronald van Vollenhoven
Murray B. Urowitz
Affiliated Authors:
Anca Askanase
Andrew S. Bomback
Columbia Affiliation:
Subjects:
Lupus Erythematosus, Systemic (MeSH)
Immunosuppressive Agents (MeSH)
Systemic Lupus Erythematosus and Antiphospholipid Syndrome (OpenAlex Topic)
Therapeutic Antibodies: Development, Engineering, and Applications (OpenAlex Topic)
Immunological Mechanisms in Atherosclerosis Development (OpenAlex Topic)
Author Keywords:
biological products
glucocorticoids
lupus nephritis
systemic lupus erythematosus
elink
Publication Type:
Article
Unique ID:
10.1136/lupus-2023-001124
PMID:
38777595
DOI:
10.1136/lupus-2023-001124
Journal:
Lupus Science and Medicine
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record

Record Created: